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Drug Administration (FDA), which regulates antibiotic use in humans and animals, has introduced a 
voluntary plan for animal pharmaceutical companies to phase out the use of certain antibiotics that are 
considered medically important for people in order to avoid the development of drug resistant bacteria.14 
 
Regulatory history 
The use of hormones in animal agriculture has a troubling past. The first hormone approved for farmed 
animal use in the United States was diethylstilbestrol (DES), which was authorized in oral form for growth 
promotion in cattle in 1954, followed by implant use for cattle and sheep in 1956.15 Use of DES spread 
rapidly and, at its peak use, approximately 80-95% of all cattle were administered the hormone in some 
form. However, concerns over carcinogenic properties plagued DES throughout the period of its approved 
use until 1979, when the FDA banned all use of DES in cattle and sheep following the discovery of a form 
of cancer in the daughters of human mothers who had DES administered to prevent miscarriages.16  
The hormones and beta-agonists currently approved for use in cattle and swine in the United States are listed 
in the table below. 
 
Table 1. Hormone and beta-agonist drugs approved for use in animal 
production in the United States17,18,19 
Type Name Delivery mode Species Year approved 
naturally-occurring 17 beta-estradiol Ear implant Beef cattle 1956 
naturally-occurring testosterone Ear implant Beef cattle 1958 
naturally-occurring progesterone Ear implant Beef cattle 1956 
synthetic trenbolone acetate (TBA) Ear implant Beef cattle 1987 
synthetic zeranol Ear implant Beef cattle and sheep 1969 
synthetic melengestrol acetate Feed additive Beef cattle 1968 
synthetic20 ractopamine Feed additive 
Beef cattle, swine and 
turkeys21 2003
22 
synthetic23 zilpaterol Feed additive Beef cattle 200624 
synthetic25 
recombinant bovine growth 
hormone (rBGH) 
Injection Dairy cattle 199326 
 
In contrast to the United States, the European Union has banned the use of growth-promoting hormones due 
to consumer health and safety concerns. The European Union issued a series of Directives in the 1980s that 
placed restrictions on the use of substances having thyrostatic, oestrogenic, androgenic, or gestagenic action, 
first restricting their administration to therapeutic purposes in 1981,27 then restricting the movement of 
animals administered such substances between member states, as well as the import of such animals from 
non-European Union countries in 1988.28 In 199629 and 2003, the European Union amended its regulations, 
but maintained the ban, and included beta-agonists.30 
The Scientific Committee on Veterinary Measures Relating to Public Health’s 1999 report to the European 
Commission presented a scientific assessment of the effects of hormone-treated meat on human health, 
identifying several areas of concern. These included potential neurobiological, developmental, reproductive, 
and immunological effects, as well as potential immunotoxicity, genotoxicity, and carcinogenicity. 17 beta-
estradiol in particular was recognized as having carcinogenic properties due to its tumor-initiating and 
tumor-promoting effects, while prepubescent children were identified as the group most at risk. As the 
findings did not yield a quantitative estimate of risk, no acceptable threshold levels have been established for 
hormone use.31 
rBGH was first permitted in the United States in 1993 when the FDA approved Posilac, manufactured by the 
Monsanto Company.32 However, numerous other countries, including EU member states, Canada, Japan, 
Australia, and New Zealand have prohibited the use of rBGH for dairy cows.33 The ban in Europe was based 
on animal health and welfare concerns (discussed below), but historically, uncertainty regarding potential 
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human health risks and agricultural policy considerations were also at issue.34 Although not administered to 
cows in the European Union, dairy products from rBGH-treated cows may still be imported and sold there.35 
 
The welfare of cattle and sheep treated with growth hormones 
The effects of hormone use on animal welfare have been most widely studied in connection with rBGH use 
in dairy cows. One of the most recognized side effects of rBGH is mastitis, or inflammation of the mammary 
gland. Monsanto’s own studies, conducted for the purpose of obtaining FDA approval, found that use of 
Posilac increased risk for clinical mastitis.36  
Subsequent studies suggest that an increase in mastitis may not be due to rBGH treatment per se, but rather 
to the increase in productivity caused by rBGH, the same as would be expected when genetic selection leads 
to greater milk production.37 Regardless of its cause, clinical mastitis is a serious animal welfare issue, and 
can be fatal in severe cases. It is one of the leading causes of cow mortality.38 Mastitis has other significant 
implications for animal welfare, as it is known to cause pain in the udder,39 as well as fever and depression.40  
Despite widespread recognition of the increased risk for the disease, the FDA did not address the animal 
welfare implications of mastitis in its decision to approve rBGH use. It focussed instead on the human health 
risk posed by the possible increased use of antibiotics to treat the mastitis,41 while stating that its approval 
“…does not mean that there are no risks of adverse effects to the treated animal.”42 
rBGH has also been associated with clinical lameness and skeletal disorders in dairy cows. These diseases 
were most prominently documented through a post approval monitoring program (PAMP) carried out by 
Monsanto and published in 1996. The PAMP revealed an increased prevalence of many musculoskeletal 
disorders in rBGH-treated cows compared to the control group, with the number of multi-parous cows (those 
who have given birth more than once) having foot disorders at a rate 2.2 times higher than control cows, and 
with the number of days affected 2.1 times higher for rBGH-treated animals than in the control group.43 
Another animal welfare implication of rBGH used in dairy cows is irritation at the injection site. Pooled 
results from three clinical trials showed that administration of 500 mg of rBGH every 14 days during 
lactation resulted in numerous animals having visible swelling at the injection site and/or other 
complications (e.g., draining, lesion, hematoma, etc.).44,45 
Additional health issues that have been observed in dairy cattle administered rBGH include: lower 
pregnancy rate, indicating failure to conceive; increased frequency of multiple births; lower body condition 
score at the end of the lactation period; and digestive disorders such as bloating, indigestion, and diarrhea. 
As an indication of overall impact on animal welfare, higher culling (selection for removal and slaughter or 
euthanasia) rates have been observed for cows treated with rBGH.46 There is also evidence that cows treated 
with rBGH are more prone to heat stress under high environmental temperatures.47 
In contrast to the effects of rBGH on dairy cows, little is known about the effects of hormones on the welfare 
of cattle used in meat production. However, evidence suggests that hormone usage can have adverse effects 
on cattle under certain climactic conditions. A 2005 study found that in temperatures nearing 30º C (86º F), 
estrogen implants in cattle limit heat loss, increasing heat stress and the potential for death from heat 
episodes.48 Additionally, 2013 research into the use of zeranol implants in lambs linked it with incidence of 
vaginal and rectal prolapse and overall mortality, both of which increased linearly with higher dosages used 
in the study.49 
 
The welfare of cattle and swine treated with beta-agonists 
 
The beta-agonists ractopamine hydrochloride (sold as Optaflexx by Elanco) and zilpaterol hydrochloride 
(sold as Zilmax by Intervet, a subsidiary of Merck & Co.) are FDA approved drugs used to promote weight 
gain and growth of lean muscle in cattle. They are mixed into feed during the final 20 to 42 days prior to 
slaughter.50,51 However, beta-agonists provide no health benefits to the cattle themselves52 and their use has 
concerning implications for animal welfare.53 
 
4 
An HSUS Report: Welfare Issues with the Use of Hormones and Antibiotics in Animal Agriculture 
 
In 2013, cattle expert Dr. Temple Grandin noted that “[w]hen beta-agonists first came on the market, I 
observed some strange new problems in fed cattle when they arrived at the packing plant. Brahman crosses, 
Holsteins, and many other types of cattle had occasional lots where on hot summer days cattle arrived that 
were stiff and sore footed. A few animals went down and had severe heat stress symptoms.”54 Issues with 
Zilmax came to a head at a meeting of the National Cattlemen’s Beef Association (NCBA) in August 2013. 
During the meeting Lily Edwards-Calloway from JBS, a major U.S. meat processor, showed a video of 
lame, stiff-gaited cattle. She explained that at least 20% of the cattle arriving at two JBS plants during hot 
summer weather were “tender-footed,” and more difficult to move out of holding pens.55,56 At the same time, 
Tyson Foods Inc. informed its suppliers that it would stop buying cattle fed Zilmax effective September 6, 
2013, due to concerns that Zilmax may have been a factor in cattle showing up at slaughter plants unable to 
walk or move.57 ,58 Immediately following this, Merck announced that it was confident that problems 
witnessed by Tyson were not caused by Zilmax.59 Five days later, Merck offered to conduct audits for 
packers and processors to determine potential causes of mobility problems in cattle.60 However, by the 
following week, Merck announced that it was temporarily suspending sales of Zilmax in the United States 
and Canada while it conducted its audits and studies.61,62 Merck’s plan to conduct studies on Zilmax were 
stalled as cattle producers refused to participate, instead switching to the older drug ractopamine.63,64  
 
Subsequent studies have confirmed the welfare implications of zilpaterol. Researchers in 2014 found that 
death rates in cattle consistently increased across datasets in response to the administration of zilpaterol. 
However, the use of ractopamine was equally problematic. The cumulative risk of mortality was 75-90% 
greater when cattle were given either beta-agonist, and these results could not be explained by other co-
variables in the study. The study emphasized that while cattle death is an uncommon event in feedlots, 
administration of FDA-approved beta-agonists substantially increases death incidence.65 
 
A separate 2014 study investigating the behavioral effects of zilpaterol administered to cattle (in 
combination with an implant of trenbolone acetate and estradiol) found significant effects on the behavior of 
the animals, including more pushing and lateral lying (lying on the side of the body) among the treated 
cattle. The study authors noted that the meaning of the increase in lateral lying was unclear, but that in 
observations of cattle undergoing castration it appeared to be associated with pain.66 
 
Throughout this period, Merck has maintained that Zilmax “is safe when used according to the product label 
and in conjunction with sound animal husbandry practices.”67 In support of this, Merck cites its own studies 
conducted in support of FDA approval,68 including studies examining carcass cutability and consumer 
palatability, and undisclosed data.69  
 
Ractopamine is used not only in cattle production but may also be used in the finishing rations of swine, 
where it is sold under the trade name Paylean.70 However, feeding ractopamine to pigs causes disturbing 
animal welfare side effects. Within a couple of years of it receiving approval in 1999, questions of its safety 
began to arise, as the FDA received numerous reports of sick and dying pigs.71,72 At the request of the FDA, 
Elanco added a warning label to the product.73 
 
Between 2000 and 2003 Purdue University conducted a series of research trials to determine, among other 
things, optimal doses of Paylean for growth efficiency.74 Although part of the purpose of the studies was to 
assess the economic benefits of Paylean, researchers also found behavioural and physiological problems.75 
Studies showed that pigs finished with Paylean had elevated heart rates and catecholamine concentrations 
(indicators of stress), and showed less willingness to walk when fed the drug.76,77,78 The Purdue studies also 
found that pigs finished with Paylean initially became more active and then more difficult to handle, and 
showed heightened reactions in response to transportation. 79  
 
Researchers further determined that the pigs’ reluctance to move may put them more at risk from rough 
handling during loading and unloading, as there was a marked increase in the number of pats, slaps, and 
pushes stockpersons used,80 impairing the welfare of the pigs.81 These concerns were restated in a 2015 
University of Illinois study, which corroborated that ractopamine affected metabolic and physiological 
responses of pigs, and that pigs subjected to aggressive handling showed increased open-mouthed breathing 
and skin discoloration.82 Continued studies with increasing focus on animal welfare have determined that 
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pigs also showed greater susceptibility to fearfulness, as indicated by increased heart rates and immobility,83 
abnormal behavior,84 increased impulsive aggression,85,86,87 and a greater frequency of hoof lesions.88  
 
Antibiotic resistance – consequence for animal health and welfare 
 
In addition to the routine use of hormones in commercial animal agriculture, the administration of antibiotics 
is also of concern. Antibiotics are administered to farm animals for three primary reasons: therapeutically to 
treat disease, prophylactically to prevent expected disease, and routinely as a growth promoting drug.89 The 
therapeutic use of antibiotics to improve the health of sick animals is important to their welfare. The use of 
antibiotics as growth promotors and prophylactically, however, are contentious practices, because feeding 
low doses for extended periods of time can lead to antibiotic resistant bacteria.90 
 
Table 2. Subtherapeutic antibiotic use in farm animals91  
Animal type Antibiotic use Delivery mode 
Swine prophylaxis or growth promotion feed 
Feedlot cattle prophylaxis or growth promotion feed or water 
Veal and dairy calves prophylaxis or growth promotion92 milk or milk replacer 
Dairy cows prophylaxis intramammary infusion 
Broiler chickens prophylaxis or growth promotion feed or water 
Turkeys prophylaxis or growth promotion feed or water 
Hatching eggs prophylaxis dipping or injection 
 
Much has been written about the potential human health threat resulting from antibiotic-resistant bacteria.* 
However, antibiotics are also used to treat sick non-human animals, whose health can also be threatened by 
antibiotic resistance.93 A number of different contagious bacterial diseases cause illness and suffering in 
animals raised for food.94,95 Respiratory and enteric diseases are among the most common in pigs and cattle, 
and, as previously discussed, mastitis is common in cows used for milk production.96 Because these diseases 
are contagious they can be more readily spread when animals are kept in large groups and crowded together, 
as researchers found with bovine respiratory disease in feedlots.97  
 
Some antibiotics are already no longer recommended as first-line choices for treating animal diseases 
because of bacterial resistance. Emergence of penicillin or tetracycline resistance in Pasteurellamultocida 
and Mannheimiahaemolytica, which cause pneumonia in calves, has rendered these antibiotics less effective 
under intensive rearing conditions for veal production.98,99 Similarly, resistance to drugs previously used to 
control swine dysentery (a serious enteric infection in growing pigs caused by Brachyspirahyodysenteria), 
such as tylosin and lincomycin, is now widespread. However, resistance to pleuromutilins, another drug 
used to control these infections, has also been reported, increasing the difficulty of controlling swine 
dysentery.100,101 
 
Methicillin-resistant Staphylococcus aureus (MRSA) has become common among pigs, and is also 
appearing among other animals used in food production.102 Reports of MRSA in milk from dairy cows, 
sometimes in association with mastitis, are increasing.103,104,105,106 MRSA isolated from dairy cows has 
generally been resistant to penicillins as well as tetracyclines and sometimes to other antibiotics as 
well.107,108 
 
Given the potential human and animal health concerns, the widespread use of antibiotics for growth 
promotion has been restricted in the European Union since 2006.109 The experience in Denmark is 
instructive, as the use of antibiotics for growth promotion was banned there even earlier, in 2000. Without 
                                                 
* For more information, see “An HSUS Report: Human Health Implications of Non-Therapeutic Antibiotic Use in 
Animal Agriculture” at www.humanesociety.org/assets/pdfs/farm/HSUS-Human-Health-Report-on-Antibiotics-in-
Animal-Agriculture.pdf. 
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antibiotics, Denmark initially had difficulty weaning piglets in the conventional way, because of problems 
with infection and diarrhea,† and piglet mortality increased following the ban. However, pig farmers were 
able to bring the mortality rate back down by implementing improved animal husbandry practices, including 
weaning piglets at a later age, improving nutrition, and increasing space per animal.110 Overall swine 
mortality rates have been shown to be similar before and after the ban.111 As with pigs, mortality did not 
increase in Danish broiler flocks after the ban on growth promoting antibiotics.112 
 
The situation in Denmark is evidence that improved animal husbandry practices, resulting in better animal 
health, can reduce the need for antibiotics. In the United States, producers report that additional management 
practices such as providing bedding for newborn calves, and allowing greater access to the outdoors and 
more space per animal are good preventative measures.113 Certainly, it is preferable to prevent disease by 
making sanitary and animal welfare improvements, rather than by using drugs as a crutch for poor 
management.  
 
The use of both hormones and antibiotics are not permitted in organic agriculture.114 Organic producers are 
required to provide outdoor access, shade, shelter, fresh air, clean water, and direct sunlight, better ensuring 
that animals can express their natural behavior.115 While organic products produced in the United States 
cannot be derived from any animal treated with antibiotics,116 organic producers are also not permitted to 
withhold antibiotics from an animal needing treatment in order to preserve the animal’s organic status.117 
However, it has been speculated that the economic impact of the loss of organic status of an animal could 
incentivize some farmers to delay antimicrobial treatment when it is needed, which could prolong any 




The push to engineer ever increasing levels of productivity in animal agriculture has serious welfare 
consequences for animals. While hormones and hormone-like drugs must be tested for consumer safety in 
the United States, comparative monitoring for animal welfare effects has not been emphasized. Research is 
beginning to reveal concerning side effects and unintended outcomes for the use of these drugs, even when 
approved and regulated. 
 
The use of antibiotics in agriculture must be more carefully scrutinized, for both human and animal health 
reasons. It is unlikely that any new antibiotic classes will be developed in the area of veterinary medicine, 
with research focusing instead on human health. However, this may be an incentive towards better animal 
welfare, both through encouraging greater care to prevent disease in the first place, and in limiting the use of 
antibiotics to more judicious treatment of infectious diseases.119  
 
There is a growing demand for animal products raised without antibiotics and hormones. Many major food 
companies are enacting policies to eliminate or reduce the use of one or both in their supply chains, 
including Panera Bread,120 Chipotle,121 Starbucks,122 and McDonalds.123 The sale of organic food continues 
to grow.124 In 2015, California became the first state in the Nation to prohibit the use of low doses of 
antibiotics to enhance growth or prevent disease in healthy animals.125 Reliance on growth promoting 
pharmaceuticals may decrease in the years ahead, and such a development would be a promising outcome 
for the welfare of farmed animals. 
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